Jennifer M Specht

List of Publications by Year
in descending order

35 papers	1,862 citations	361413 20 h-index	414414 32 g-index
35 all docs	35 docs citations	35 times ranked	2582 citing authors

#	Article	IF	Citations
1	Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases. Journal of Experimental Medicine, 1997, 186, 1213-1221.	8.5	297
2	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3840-3847.	1.6	253
3	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell, 2021, 39, 193-208.e10.	16.8	157
4	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4449-4457.	1.6	142
5	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 4799-4805.	7.0	120
6	Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment, 2007, 105, 87-94.	2.5	97
7	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. Clinical Cancer Research, 2011, 17, 2400-2409.	7.0	94
8	A Phase 2 Study of 16Î±-[18F]-fluoro-17Î²-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Molecular Imaging and Biology, 2014, 16, 431-440.	2.6	80
9	Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer. Clinical Cancer Research, 2010, 16, 2803-2810.	7.0	72
10	Kinetic Analysis of¹⁸F-Fluoride PET Images of Breast Cancer Bone Metastases. Journal of Nuclear Medicine, 2010, 51, 521-527.	5.0	65
11	Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Seminars in Radiation Oncology, 2009, 19, 222-228.	2.2	51
12	Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient. Clinical Cancer Research, 2009, 15, 5294-5296.	7.0	43
13	Association between serial dynamic contrastâ€enhanced MRI and dynamic ¹⁸Fâ€FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Magnetic Resonance Imaging, 2010, 32, 1124-1131.	3.4	41
14	Prospective Study of Serial ¹⁸F-FDG PET and ¹⁸F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 1823-1830.	5.0	41
15	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. Clinical Cancer Research, 2013, 19, 1884-1893.	7.0	38
16	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2019, 37, 714-722.	1.6	36
17	Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Research, 2012, 14, 206.	5.0	32
18	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Research, 2012, 2, 34.	2.5	27

#	Article	IF	Citations
19	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancerâ€"A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clinical Breast Cancer, 2019, 19, e283-e296.	2.4	24
20	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2247-2256.	1.6	22
21	Testâ€"Retest Reproducibility of ¹⁸F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. Journal of Nuclear Medicine, 2019, 60, 608-614.	5.0	21
22	¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2â^' Metastatic Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 184-190.	5.0	20
23	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, e143-e149.	2.4	15
24	Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007â€"2016. Radiology, 2021, 300, 290-300.	7.3	13
25	[¹⁸F]Fluorodeoxyglucose Positron Emission Tomographyâ€"Computed Tomography in Breast Cancer: Whenâ€¦ and When Not?. Journal of Clinical Oncology, 2012, 30, 1252-1254.	1.6	11
26	Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2020, 181, 255-268.	2.5	11
27	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. Breast Cancer Research, 2021, 23, 88.	5.0	11
28	Facility Variability in Examination Indication Among Women With Prior Breast Cancer: Implications and the Need for Standardization. Journal of the American College of Radiology, 2020, 17, 755-764.	1.8	9
29	Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, 1089-1089.	1.6	8
30	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. Clinical Breast Cancer, 2015, 15, e277-e285.	2.4	6
31	A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clinical Breast Cancer, 2022, 22, 32-42.	2.4	4
32	Optimal duration of trastuzumab for early HER2-positive breast cancer. Lancet, The, 2017, 389, 1167-1168.	13.7	1
33	Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.. Journal of Clinical Oncology, 2012, 30, TPS3109-TPS3109.	1.6	0
34	Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival.. Journal of Clinical Oncology, 2012, 30, 1088-1088.	1.6	0
35	A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 1090-1090.	1.6	0